# Jean Stimola-Sposaro

Jean Stimola-Sposaro writes about clinical research, with a focus on making trials more accessible and patient-centered. Their posts examine barriers to participation, decentralized trial design, and governance of clinical-trial data.

- Profile: https://b2binfluencer.marketing/creators/jean-stimola-sposaro/
- LinkedIn: https://www.linkedin.com/in/jean-stimola-sposaro-msj-72418158
- LinkedIn followers: 3,089
- Based on 11 dated posts, latest 2026-09-18

## Summary

They are useful for research-led commentary on patient-centered trial design, access barriers, and clinical-trial data governance.

- Best for: Clinical research technology or data-governance campaigns needing patient-centered thought leadership and joint analysis.
- Not for: Consumer health or patient-recruitment campaigns seeking high-volume promotional placements, product-first messaging, or conversion results.
- Check first: Confirm audience demographics by job function and any comparable sponsored post results.

### Takeaways

- Trial participants should own the health data collected from them
- Decentralized trial design can quietly rebuild the access barriers it was meant to remove
- Access barriers are infrastructure costs and belong in the protocol budget

## Main ideas

- **Trial participants should own the health data collected from them**: Jean responded to a compliance analysis separating investigator-controlled clinical data from sponsor-managed operational data in trial technology systems. They accept the clarification as useful and overdue, but argue it stops short: the framework still treats data as something sponsors and investigators divide between themselves, leaving participants out. In their argument, protocol-required monitoring data belongs by rights to the person it was gathered from, not to either party. They distinguish individual participant health data from study results, noting that even as the NIH pushes for the return of study results, the first category remains undefined. They ask whether participant health-data classification should be a mandatory field in protocol design rather than an afterthought. The post calls for a patient-preference data-ownership model and a measurable data-integrity framework, then asks what funding the commons would actually require.
- **Decentralized trial design can quietly rebuild the access barriers it was meant to remove**: Jean summarized a two-round Delphi study in which 26 experts across 13 countries prioritized solutions to six persistent barriers facing decentralized clinical trials in Europe: provider burden, investigational product and biosample logistics, collaboration with local healthcare resources, regulatory harmonization, knowledge gaps, and digital technology barriers. The panel reached at least 80% agreement on 32 of 39 synthesized recommendations. Its highest-priority fix was training and support for the healthcare professionals running the trials, not a technology purchase. Jean also highlights where consensus broke down: proposals to centralize ethics review at the EU level and enable peer-to-peer participant support failed to reach agreement. They read this as a sign that the field has yet to agree on how far harmonization should go and where national and local nuance matters. The post ends by asking whether a large consent-stage drop-off reflects a digital-literacy problem, a consent-design problem, or the fact that decentralized and equitable are not automatically the same thing.
- **Access barriers are infrastructure costs and belong in the protocol budget**: Jean argues that the field writes statistically elegant eligibility criteria, then underfunds the logistics that determine who can actually walk through the door. They conclude that equitable access requires infrastructure investment in the protocol budget alongside monitoring and site payments—not a recruitment slide or optional patient-support add-on. They ask what it would look like if trial budgets treated caregiver and housing support as required line items.
- **Equity becomes structural when policy covers participation costs—and that work has to be pre-competitive**: Jean covered the bipartisan Clinical Trial Modernization Act (S.4440/H.R.3521), which would let sponsors cover non-medical participation costs such as travel, lodging, food, and parking alongside medical copays, and support remote-participation technology. The bill targets enrollment barriers that keep racial and ethnic minorities, older adults, and rural populations underrepresented. Jean frames it as making equity in access structural rather than aspirational, with policy catching up to the decentralized, digital, and remote-participation tools the field has been building. The post asks sponsors already piloting travel or lodging reimbursement what has actually changed in enrollment diversity numbers and what the bill would unlock that voluntary practice cannot. In other posts, Jean argues that standards organizations often work in isolation, blocking real-time opportunities to improve trustworthiness, and points to pre-competitive, cross-stakeholder efforts such as the Digital Trials & Research Alliance.

## Work to read

- [Delphi study on barriers to decentralized clinical trials in Europe](https://www.linkedin.com/posts/jean-stimola-sposaro-msj-72418158_key-challenges-of-dct-trials-in-europe-delphi-activity-7485291800555937792-xCO8)
- [Who owns the data in a clinical trial?](https://www.linkedin.com/posts/jean-stimola-sposaro-msj-72418158_clarifying-ownership-of-irt-data-in-clinical-activity-7500285969145872384-yur5)
- [The “showstopper” barriers to trial access aren’t what we usually fund](https://www.linkedin.com/posts/jean-stimola-sposaro-msj-72418158_equity-in-clinical-trials-aml-transplant-activity-7506750751185063937-9cJ-)
- [Nearly 200 patient and provider groups endorse the Clinical Trial Modernization Act](https://www.linkedin.com/posts/jean-stimola-sposaro-msj-72418158_nearly-200-patient-public-health-and-health-activity-7483149912373743616-O9I1)

## Brand relationships

- **Digital Trials & Research Alliance (DTRA)** (mention)
- **EquitiD LLC** (mention)

## Partnerships

Jean Stimola-Sposaro's posts do not publish sponsorship formats, a rate card, media kit, or partnership page. They show an open, topic-led style of collaboration: one post closes with an explicit invitation to work together on decentralized-clinical-trial frameworks ("We would love to work with you"), while another asks their network what would move enrollment diversity. Posts include hashtags such as #dtra and #equitidellc, but do not identify a sponsored format. Buyers would need to negotiate directly; ask about available formats, rates, and the best inquiry route.

## Alternatives

- Pamela Shaddock: Pick Pamela Shaddock over Jean Stimola-Sposaro when the campaign is about the patient's experience inside the care system rather than about how trials are designed and governed. The same clinical research technology company would choose Pamela Shaddock if it wanted a partner who has already built a patient-facing product into hospital operations: since 2019 Pamela Shaddock has co-founded and run Coils to Locs, a textured-wig company for medical hair loss, and the posts show 27-plus hospital and cancer centre partnerships with a stated goal of 40 by the end of 2026, a 'Wigs 101 for Alopecia Areata' webinar for the National Alopecia Areata Foundation, a live presentation and panel at the 41st Annual NAAF Conference in Orlando, an 'Ask For Coils to Locs By Name' campaign running with hospital partners, and a $25,000 Chasm Momentum Grant plus a $1,000 Rockland Trust award. A campaign that needs a collaborator who can speak about patient dignity, oncology nursing, hospital retail, and how a patient-facing product actually gets stocked and recommended is served better here than by a research analyst.
- Bami Adenipekun: Choose Bami Adenipekun when the campaign is about how health systems treat people, not how trials run. For companies focused on patient voice, cultural safety, or community engagement, Adenipekun brings lived experience of the system alongside formal training in it. The posts describe a mother's death from cancer, a sister's later diagnosis and Adenipekun's own, a master's in International Development and Human Rights, and the move into patient advocacy that followed. They also feature a book, 'Navigating Your New Normal: A Road Map For Life Fulfilment After Trauma'. The clearest working example is the 'Seen Heard Valued' event for 9 September with NHS Wales. It centres on the argument that most healthcare community engagement stops at the survey and never returns to say what changed—a point a health-equity campaign can build on.
- Hussain Mooraj: Choose Hussain Mooraj when the goal is reaching cell and gene therapy decision-makers in one room rather than publishing an argument. The posts show Hussain Mooraj co-hosting the NextGen Therapy EMEA Industry Working Group in Rome and running the 2026 Deloitte NextGen Therapies Industry Working Group Spring Summit at Deloitte University, with named speakers spanning clinical delivery, manufacturing, investment, and AI, and a LinkedIn community hub that people can join to continue the discussion. The content is pitched at the access problem at enterprise scale, with specific numbers worth quoting: fewer than one in five eligible patients able to reach these therapies, one company reporting cost of goods under $8,000, 90% of the room using AI daily, and investors now asking how a therapy will reach a patient before they commit. For a campaign that needs payer, policy, and manufacturing executives in the audience, this is a more direct route than a research-led commentary series.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/